Please assess the completion status of the following clinical trial:

Trial Title: Drotaverine to Shorten the Length of Labor

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Women aged between 18 and less than 35 years.~* Primigravidae.~* Singleton pregnancy.~* Term gestation i.e., 37-42 weeks.~* Sure, reliable dates documented by ultrasound in the 1st half of pregnancy.~* Vertex presentation with occipito anterior position~* Regular uterine contractions at a rate of at least 3 to 4 contractions every 10 minutes, each contraction lasting for at least 40 seconds.~* Cervical dilatation of 3-5 cm.~* With or without rupture of membranes~* No evidence of maternal or fetal distress.~Exclusion Criteria:~* Cephalo-pelvic disproportion.~* Cervical surgery in the past or history of cervical injury.~* Patients on antihypertensive therapy.~* Known hypersensitivity to Drotaverine hydrochloride.~* If any other spasmolytic agent had been used within 48 hours.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 35 Years
- Healthy Volunteers: f

Study Arms:
- Drotaverine (Type: ACTIVE_COMPARATOR): Women who will receive 40 mg Drotaverine hydrochloride (Do-Spa) IV injection.
- Placebo (Type: PLACEBO_COMPARATOR): Women who will receive 2ml of normal physiological saline (0.9% sodium chloride) I.V.

Based on this trial design, predict the completion outcome and termination type (if applicable).